Marianne Klemp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6955740/publications.pdf

Version: 2024-02-01

257450 254184 2,974 50 24 43 h-index citations g-index papers 51 51 51 3882 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. International Journal of Cancer, 2001, 92, 441-450.	5.1	261
2	Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. British Journal of Cancer, 2006, 95, 1474-1482.	6.4	260
3	Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13255-13260.	7.1	233
4	Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2006, 55, 1553-1564.	4.2	220
5	Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open, 2014, 4, e004587.	1.9	215
6	Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet, The, 1995, 346, 1399-1400.	13.7	200
7	Longâ€term followâ€up of patients with resected pancreatic cancer following vaccination against mutant Kâ€ras. International Journal of Cancer, 2011, 128, 1120-1128.	5.1	156
8	Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation., 1997, 72, 784-790.		147
9	Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open, 2012, 2, e000653.	1.9	146
10	Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010. Pharmacoeconomics, 2014, 32, 367-375.	3. 3	134
11	What principles should govern the use of managed entry agreements?. International Journal of Technology Assessment in Health Care, 2011, 27, 77-83.	0.5	123
12	Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study., 1996, 65, 450-453.		97
13	HPV mRNA tests for the detection of cervical intraepithelial neoplasia: A systematic review. Gynecologic Oncology, 2011, 120, 430-438.	1.4	88
14	A TGFβRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8 + T cells. Cancer Immunology, Immunotherapy, 2001, 50, 469-476.	4.2	67
15	A multiple treatment comparison metaâ€analysis of monoamine oxidase type B inhibitors for Parkinson's disease. British Journal of Clinical Pharmacology, 2018, 84, 1917-1927.	2.4	54
16	More Use of Peritoneal Dialysis Gives Significant Savings: A Systematic Review and Health Economic Decision Model. Journal of Clinical Medicine Research, 2017, 9, 104-116.	1,2	49
17	Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. International Journal of Technology Assessment in Health Care, 2011, 27, 253-260.	0.5	45
18	Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation. Pharmacoeconomics, 2014, 32, 601-612.	3.3	43

#	Article	IF	Citations
19	Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Experimental Dermatology, 2001, 10, 161-167.	2.9	41
20	Health technology assessment to optimize health technology utilization: Using implementation initiatives and monitoring processes. International Journal of Technology Assessment in Health Care, 2010, 26, 309-316.	0.5	37
21	A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis. Journal of Clinical Medicine Research, 2018, 10, 88-105.	1.2	33
22	Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer. Vox Sanguinis, 1998, 74, 489-495.	1.5	32
23	Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. British Journal of Cancer, 1996, 74, 1828-1833.	6.4	29
24	A Review and Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical Neuroleptic Drugs Compared With Haloperidol and Placebo. Journal of Clinical Psychopharmacology, 2011, 31, 698-704.	1.4	29
25	Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis. European Journal of Clinical Pharmacology, 2020, 76, 1731-1743.	1.9	28
26	HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. Journal of Molecular Medicine, 2003, 81, 43-50.	3.9	26
27	HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health, 2014, 14, 867.	2.9	23
28	INTERACTION INITIATIVES BETWEEN REGULATORY, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE BODIES, AND INDUSTRY. International Journal of Technology Assessment in Health Care, 2012, 28, 374-381.	0.5	20
29	Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. BMJ Open, 2017, 7, e014880.	1.9	18
30	Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. PLoS ONE, 2015, 10, e0137258.	2.5	15
31	Common adverse events associated with an SSRI: metaâ€analysis of early paroxetine data. Pharmacoepidemiology and Drug Safety, 2008, 17, 707-713.	1.9	14
32	Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era. Journal of Public Health, 2012, 34, 539-547.	1.8	13
33	NEW ANTICOAGULANTS AS THROMBOPROPHYLAXIS AFTER TOTAL HIP OR KNEE REPLACEMENT. International Journal of Technology Assessment in Health Care, 2013, 29, 234-243.	0.5	12
34	Generation and characterization of GP-100 peptide-specific NK-T cell clones., 1998, 75, 794-803.		11
35	ENDPOINTS FOR RELATIVE EFFECTIVENESS ASSESSMENT (REA) OF PHARMACEUTICALS. International Journal of Technology Assessment in Health Care, 2014, 30, 508-513.	0.5	11
36	Combination of GM-CSF with antitumour vaccine strategies. European Journal of Cancer, 1999, 35, S33-S35.	2.8	10

#	Article	lF	CITATIONS
37	Meta-Regression Analysis of Paroxetine Clinical Trial Data. Journal of Clinical Psychopharmacology, 2011, 31, 201-206.	1.4	6
38	Critical appraisal of adverse effects reporting in the â€~Treatment for Adolescents With Depression Study (TADS)'. BMJ Open, 2019, 9, e026089.	1.9	6
39	Adverse effects information in clinical guidelines on pharmacological treatment of depression in children and adolescents: a systematic review. BMJ Open, 2020, 10, e036412.	1.9	6
40	Responsibility and accountability for well informed health-care decisions: a global challenge. Lancet, The, 2015, 386, 826-828.	13.7	4
41	A phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer. Journal of Clinical Oncology, 2005, 23, 2580-2580.	1.6	4
42	Characterization of gastrointestinal adverse effects reported in clinical studies of corticosteroid therapy. Journal of Clinical Epidemiology, 2018, 94, 19-26.	5.0	2
43	Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors. Parkinson's Disease, 2021, 2021, 1-7.	1.1	2
44	Mutant ras peptide vaccines. European Journal of Cancer, 1997, 33, S289.	2.8	1
45	Do Various Glitazones Have the Same Risk of Acute Myocardial Infarction? Indirect Evidence from a Population-Based Norwegian Cohort Study. The Open Diabetes Journal, 2009, 2, 62-68.	0.4	1
46	TRANSCATHETER AORTIC VALVE IMPLANTATION AND ADAPTIVE / PROGRESSIVE COVERAGE. International Journal of Technology Assessment in Health Care, 2014, 30, 250-251.	0.5	0
47	Expansion of the Norwegian HPV Vaccination Program. Value in Health, 2014, 17, A636.	0.3	0
48	Eunethta Tools and Methods – Facilitating Uptake by Training Activities. Value in Health, 2015, 18, A561.	0.3	0
49	Are Both Antidepressant Drug Effects and Test Scores Unspecific?. Journal of Pharmacological & Biomedical Analysis, 2014, 02, .	0.6	0
50	Parkinson's disease, treatment choice and survival over time. Clinical Parkinsonism & Related Disorders, 2022, 6, 100136.	0.9	0